Solid Biosciences Inc. (NASDAQ:SLDB – Free Report) – Chardan Capital raised their FY2025 earnings estimates for shares of Solid Biosciences in a research report issued to clients and investors on ...

Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...

Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key functions of full-length dystrophin and allows it be delivered more effectively ...

Shares of biotech company Solid Biosciences (NASDAQ: SLDB) skyrocketed on Feb. 18 after the firm released key clinical data.

In a report released today, Gena Wang from Barclays maintained a Buy rating on Solid Biosciences (SLDB – Research Report), with a price target ...

Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which ...

Solid Biosciences (SLDB) stock surges after strong Phase 1/2 data for its Duchenne therapy SGT-003. Read more here.